GLP-1 Dosing Guide: Complete Semaglutide & Tirzepatide Escalation Schedules and Timing

Semaglutide follows a five-step dose escalation protocol designed to gradually acclimate the body to the medication and reduce gastrointestinal side effects. The schedule for weight management (Wegovy dosing) is as follows: 0.25 mg weekly for weeks 1 through 4, 0.5 mg weekly for weeks 5 through 8, 1.0 mg weekly for weeks 9 through 12, 1.7 mg weekly for weeks 13 through 16, and the maintenance dose of 2.4 mg weekly from week 17 onward. Each step lasts a minimum of four weeks, meaning the full escalation takes approximately 16 to 20 weeks to reach the therapeutic maintenance dose.

The diabetes-focused schedule (Ozempic dosing) is slightly different and more flexible: 0.25 mg weekly for weeks 1 through 4, then 0.5 mg weekly as the initial maintenance dose. From there, the dose can be increased to 1.0 mg and then to the maximum of 2.0 mg based on glycemic response and tolerability, with each increase occurring after at least four weeks. The Ozempic schedule offers more flexibility because the primary goal is blood sugar control rather than maximum weight loss, and many patients achieve adequate A1C reduction at lower doses without needing to escalate further.

The 0.25 mg starting dose is not intended to produce significant weight loss or blood sugar reduction — its purpose is purely to let your gastrointestinal system adapt to the presence of a GLP-1 receptor agonist. Many patients feel little to no appetite suppression at this initial dose, which is entirely expected and not a sign that the medication is ineffective for them. Patience during the early escalation weeks pays off substantially with better tolerability at the higher, more effective doses. Think of these initial weeks as building a physiological foundation that enables your body to handle the full therapeutic dose comfortably.

Tirzepatide has a six-step escalation schedule with more granular dose increments than semaglutide: 2.5 mg weekly for weeks 1 through 4, 5 mg weekly for weeks 5 through 8, 7.5 mg weekly for weeks 9 through 12, 10 mg weekly for weeks 13 through 16, 12.5 mg weekly for weeks 17 through 20, and the maximum dose of 15 mg weekly from week 21 onward. Each dose is delivered via a single-dose prefilled autoinjector pen that corresponds to that specific strength — you use one pen per injection and dispose of it afterward.

Not every patient needs to reach the maximum 15 mg dose. Some patients achieve excellent results at 10 mg or 12.5 mg with minimal side effects, and increasing further may not provide enough additional benefit to justify the potential for increased GI symptoms. In the SURMOUNT-1 trial, even the 5 mg dose produced an average weight loss of 15% of body weight — demonstrating that lower doses can be highly effective for many patients. Your clinician will evaluate your weight loss progress, side effect profile, blood work results, and overall response at each dose level to determine whether escalation is appropriate or whether you have found your optimal maintenance dose.

The 2.5 mg increments between tirzepatide doses (compared to the larger, less uniform jumps in semaglutide's schedule) can make escalation feel smoother and more gradual for some patients. However, the full escalation to 15 mg takes approximately 20 weeks — slightly longer than semaglutide's 16-week path to its maintenance dose. This extended timeline is intentional, as tirzepatide's dual GIP/GLP-1 mechanism produces potent metabolic effects from two receptor pathways that warrant careful, gradual introduction to optimize tolerability and give the body adequate time to adapt at each dose level.

GLP-1 injections should be administered once per week on the same day each week. You can choose any day that fits your schedule — there is no medical advantage to one day over another, and the medication works equally well regardless of which day you select. Some patients prefer injecting on a weekend day when they can rest at home if mild side effects occur, while others prefer a weekday to maintain a consistent routine tied to their work schedule. The injection can be given at any time of day, with or without food, since the medication is absorbed subcutaneously and does not interact with digestive processes.

If you miss a dose of semaglutide, take it as soon as possible if there are five or more days (120 hours) until your next scheduled dose. If fewer than five days remain before your next scheduled injection, skip the missed dose entirely and resume on your regular day at the usual time. For tirzepatide, the cutoff is four days (96 hours) — take the missed dose if four or more days remain before your next scheduled dose; otherwise, skip it and resume on schedule.

Never take two doses within two days of each other to make up for a missed dose, regardless of the medication. Doubling up dramatically increases the risk of severe nausea, vomiting, diarrhea, and potentially dangerous dehydration. If you miss two or more consecutive weekly doses, contact your clinician before resuming — you may need to restart at a lower dose and re-escalate gradually to re-establish tolerability rather than jumping back to your previous dose level, which could trigger severe GI side effects. Setting a recurring weekly alarm or calendar reminder on your phone is one of the most effective strategies for maintaining consistent weekly dosing.

The standard escalation schedule is a clinical guideline, not a rigid rule that must be followed identically for every patient. Your clinician may recommend staying at a current dose longer than the standard four weeks if you are experiencing significant side effects that have not yet resolved. There is no medical disadvantage to spending extra time at any dose level — in fact, a slower, more personalized escalation often leads to better long-term tolerability, higher treatment adherence, and ultimately better weight loss outcomes because patients are less likely to discontinue treatment.

Common reasons to hold at your current dose rather than escalating include persistent nausea or vomiting that extends beyond the first week after a dose increase, inability to maintain adequate hydration or caloric intake, difficulty eating at least 1,200 calories daily for women or 1,500 calories daily for men, pronounced fatigue or weakness that interferes with daily activities, and constipation or diarrhea that has not responded to dietary adjustments. These symptoms indicate your body needs more time to adapt to the current GLP-1 receptor activation level before taking on additional stimulation from a higher dose.

In some cases, a temporary dose reduction may be the appropriate step. If side effects become severe at a new dose level — for example, persistent vomiting that prevents you from keeping food or fluids down — your clinician may reduce you back to the previous tolerated dose for two to four additional weeks before attempting the increase again. This is not a setback or a failure — it is a standard part of individualized dosing that reflects responsible clinical practice. Some patients also find that their optimal long-term maintenance dose is lower than the maximum available. If you are achieving good weight loss results at a mid-range dose with minimal side effects and high quality of life, your clinician may recommend staying there rather than pushing to the maximum.

The gradual dose escalation protocol exists because GLP-1 receptor activation produces dose-dependent effects on the gastrointestinal system. At higher doses, gastric emptying slows more dramatically, appetite suppression intensifies, intestinal motility patterns are altered more significantly, and the gut's neuroendocrine signaling is more profoundly affected. Introducing these changes abruptly — by skipping dose levels or escalating faster than recommended — leads to substantially higher rates of nausea, vomiting, diarrhea, and constipation that can be severe enough to require medical intervention.

Research from the STEP and SURMOUNT clinical trial programs provides clear evidence for the value of gradual escalation. In these trials, the majority of GI side effects occurred during the dose escalation phase and diminished as the body acclimatized to each new dose level. In STEP 1, approximately 80% of nausea episodes were rated as mild to moderate in severity, and the median duration of nausea was about eight days per dose increase before subsiding. Patients who followed the recommended escalation schedule were significantly less likely to discontinue treatment due to intolerable side effects compared to patients in earlier dose-finding studies who escalated more rapidly.

The gastrointestinal tract contains a high density of GLP-1 receptors, and the enteric nervous system (sometimes called the gut's "second brain") needs time to adapt to sustained receptor activation at each new dose level. Think of the escalation process as building tolerance — each step gives the GLP-1 receptors time to partially desensitize, so the next dose increase produces a smaller incremental GI response rather than a full-force reaction. Skipping doses or escalating too quickly bypasses this critical adaptation window, resulting in more severe and prolonged side effects that can undermine your commitment to treatment and potentially lead to early discontinuation.